Dose-ranging Study of Cannabinoid Mixtures for Rodents Set To Begin
Gb Sciences is initiating a dose-ranging study of its investigational cannabinoid-based formulations in a rodent model of Parkinson’s disease next month as a step toward a first-in-human study. The study will determine the dose range of active ingredients to be used in human trials and potential side effects.